^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer
Published date:
07/28/2020
Excerpt:
In vitro experiments in ER+ breast cancer cells confirmed that FGFR/FGF alterations led to fulvestrant resistance as well as cross-resistance to the CDK4/6 inhibitor palbociclib.
DOI:
10.1158/1078-0432.CCR-19-3958
